SCICLONE ACQUIRES EXCLUSIVE RIGHTS IN CHINA TO DC BEAD CHEMOEMBOLIZATION DEVICE

SciClone Pharmaceuticals, Inc. today announced that it has entered into a three year agreement with Biocompatibles International plc. granting SciClone exclusive rights to market Biocompatibles' DC BeadTM chemotherapy releasing device within China, particularly for the minimally invasive treatment of malignant hypervascular tumors such as primary liver cancer, hepatocellular carcinoma (HCC). Yahoo News (http://biz.yahoo.com/iw/060609/0134447.html)